Forte Biosciences, Inc. [FBRX]

Source: 

Company Overview

Forte Biosciences, Inc. and its subsidiaries is a clinical-stage biopharmaceutical company whose current lead product candidate is FB102. FB102 is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.